Ayala Pharmaceuticals Inc (ADXS)

[gold007_2000]

2018 AACR HOT summary, are these the reasons NEO terminated?

•Lm-HOT therapy enhanced antitumor efficacy and improved long-term survival.
• Lm-HOT therapy increased tumor-specific T cells and significantly decreased tumor-resident
Tregs.
• ADXS-503 therapy delays tumor growth similar to that of the KRAS_G12D_21mer Construct.
• ADXS-503 elicits effective anti-tumor immunity whether it is in a single or multi-target construct.
• ADXS-HOT platform is a promising approach to target shared hotspot mutations.